Solventum Corp Q2 FY26 Results

Summary

Solventum reported strong second-quarter 2026 financial results, with total sales increasing 2.2% to $2.2 billion and organic sales growing by 9.5%. Adjusted diluted earnings per share surged by 50.9% to $2.55, driven by improved margins and operational execution. The company also announced its intent to separate its Health Information Systems business and raised its full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow, indicating a positive outlook.

Key Highlights

1. 1

   Reported sales for the second quarter of 2026 increased by 2.2% to $2.2 billion, with organic sales growing by 9.5%.

2. 2

   Adjusted diluted earnings per share saw a significant increase of 50.9%, reaching $2.55 compared to $1.69 in the prior year period.

3. 3

   Operating cash flow for the quarter was $227 million, and free cash flow was $144 million, both ahead of expectations.

4. 4

   The company announced its intent to separate its Health Information Systems business segment as part of its transformation strategy.

5. 5

   Full-year 2026 guidance was increased for organic sales growth, adjusted EPS, and free cash flow.

6. 6

   The MedSurg segment reported net sales of $1.37 billion, an increase of 12.7% on a reported basis.

7. 7

   Dental Solutions segment net sales increased by 17.0% to $396 million.